Om Power Transmission Ltd
IPO Day 1 Subscription Status
April 9, 2026 | 2 min read
Om Power Transmission Ltd IPO Day 1 Subscriptions details: check bidding details
Om Power Transmission Ltd IPO day 1 subscription details:
The initial public offering of Om Power Transmission Ltd ended the first day with investors bidding 0.21 the available shares on offer worth 150.06. The retail investor portion of the IPO was subscribed 0.18 times the available shares on offer. Retail investors have 50.00% of the total issue reserved for them.
At the end of bidding on day 1, the qualified institutional buyers' (QIB) portion of the 53.70% got bids for 0.40 times the available shares on offer. The QIB portion includes insurance companies, domestic mutual funds, foreign institutional buyers, and other institutional investors.
The non-institutional investors quota got bids for 0.03 times the available quota of shares. This segment includes HNI and ultra HNI investors.
Here's a snapshot of the subscription details:
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIB) | 0.40 |
| Non-Institutional Investors (NII) | 0.03 |
| Retail Individual Investors (RII) | 0.18 |
| Total | 0.61 |
Om Power Transmission Ltd IPO details :
Om Power Transmission Ltd's IPO consists of an offer for sale of 17.50 shares and a fresh issue of ₹132.56. The IPO’s price band is ₹166 – ₹175 per share. The company’s shares will be listed on BSE, NSE on 17 Apr 26.
Here are the key details of Om Power Transmission Ltd IPO
Offer for sale: 17.50 shares
Fresh issue: 132.56
Price Band: ₹166 – ₹175 per share
Bid open dates: 09 Apr 26
Allotment date: 15 Apr 26
Listing date: 17 Apr 26
Check our Upcoming IPO section for new listings. Open a free demat account online with m.Stock.
More Related Articles
Symbiotec Pharmalab IPO: Date, price, lot size, everything you need to know
August 25, 2026 | 0 mins read
Symbiotec Pharmalab is a biopharmaceutical and biotechnology business that develops and manufactures active pharmaceutical ingredients, or APIs, and intermediates. The company has a strong presence in corticosteroids and steroidal hormone APIs, which are used in a range of pharmaceutical formulations. Its product portfolio also includes biotechnology-based ingredients, vitamins, minerals and nutraceutical ingredients for pharmaceutical, nutrition and wellness applications.
Augmont Enterprises Ltd IPO Day 3 Subscription Status
August 25, 2026 | 0 mins read
Augmont Enterprises Ltd is launching its IPO on 21 Aug 26. Check here the Day 3 IPO subscription status on m.Stock.
Symbiotec Pharmalab Ltd IPO Day 2 Subscription Status
August 25, 2026 | 0 mins read
Symbiotec Pharmalab Ltd is launching its IPO on 24 Aug 26. Check here the Day 2 IPO subscription status on m.Stock.